Herpes Simiae (B Virus) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

B virus, also known as Cercopithecine herpesvirus 1, is an alphaherpesvirus commonly found in macaque monkeys. It is the only non-human primate herpesvirus known to be highly pathogenic to humans and can cause severe illness if left untreated. Human infection can occur through a breach of the skin or mucosal defences, exposure to contaminated fomites, or human-to-human transmission. The nasal mucosa is less ideal for virus replication than the lung. The permissiveness of infection depends on the initial site of virus exposure and the dose of virus introduced. Symptoms of B virus infection in humans can range from a flu-like illness to neurological deterioration and can appear days to years after exposure. The array of symptoms may depend on the dose and route of inoculation and can culminate in respiratory failure. Clinical progression is associated with consistent symptoms, including flu-like illness, lymphadenitis, fever, headache, vomiting, myalgia, cramping, and urinary retention with ascending paralysis.

·       Approximately 70% of untreated patients die of complications associated with the infection. Since the B virus was identified in 1932, only 50 people have been documented to have infections.

Thelansis’s “Herpes Simiae (B Virus) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Herpes Simiae (B Virus) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Herpes Simiae (B Virus) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Herpes Simiae (B Virus) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Herpes Simiae (B Virus) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033